

What is claimed:

1. Use of an antibody-drug conjugate (ADC) comprising a bispecific antigen-binding molecule and a cytotoxin in the manufacture of a medicament for treating, reducing tumor growth, and/or causing regression of c-Met expressing uveal melanoma in a subject, wherein the subject in need thereof is to be administered the medicament, wherein the bispecific antigen-binding molecule comprises:

a first antigen-binding domain (D1); and

a second antigen-binding domain (D2);

wherein D1 specifically binds a first epitope of human MET;

wherein D2 specifically binds a second epitope of human MET;

wherein D1 comprises: a heavy chain complementarity determining region (HCDR)1 comprising the amino acid sequence of SEQ ID NO: 60; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 62; an HCDR3 comprising the amino acid sequence of SEQ ID NO: 64; a light chain complementarity determining region (LCDR)1 comprising the amino acid sequence of SEQ ID NO: 140; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 142; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 144;

wherein D2 comprises: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 84; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 86; an HCDR3 comprising the amino acid sequence of SEQ ID NO: 88; an LCDR1 comprising the amino acid sequence of SEQ ID NO: 140; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 142; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 144;

wherein the cytotoxin is a maytansinoid; and

wherein the ADC to be administered to the subject results in killing of c-Met expressing uveal melanoma cells.

2. The use of claim 1, wherein D1 comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 58 and a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 138.

3. The use of claim 1, wherein D2 comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 82 and an LCVR comprising the amino acid sequence of SEQ ID NO: 138.


4. The use of claim 1, wherein the bispecific antigen-binding molecule comprises a D1-HCVR amino acid sequence of SEQ ID NO: 58 and a D2-HCVR amino acid sequence of SEQ ID NO: 82.

5. The use of claim 1, wherein the first epitope of human MET comprises amino acids 192-204 of SEQ ID NO: 155.

6. The use of claim 1, wherein the second epitope of human MET comprises amino acids 305-315 and 421-455 of SEQ ID NO: 155.


7. The use of claim 1, wherein the first epitope of human MET comprises amino acids 192-204 of SEQ ID NO: 155; and wherein the second epitope of human MET comprises amino acids 305-315 and 421-455 of SEQ ID NO: 155.

8. The use of claim 1, wherein the cytotoxin is conjugated to the bispecific antigen-binding molecule through a linker, and wherein the cytotoxin is:




wherein the  is the bond to a linker.

9. The use of claim 8, wherein the linker is:




wherein the bond noted with A represents the bond to the bispecific antigen-binding molecule and the bond noted with P represents the bond to the cytotoxin.

10. The use of claim 1, wherein the cytotoxin is conjugated to the bispecific antigen-binding molecule through a linker, and wherein the cytotoxin is:



wherein the --- is the bond to the linker.

11. The use of claim 10, wherein the linker is:



wherein the bond noted with $\sim^A$ represents the bond to the bispecific antigen-binding molecule and the bond noted with $\sim^P$ represents the bond to the cytotoxin.

12. Use of an antibody-drug conjugate (ADC) comprising a bispecific antigen-binding molecule and a cytotoxin in the manufacture of a medicament for inhibiting proliferation, inhibiting invasion, causing apoptosis, and/or decreasing viability of a c-Met expressing uveal melanoma cell, wherein the cell is to be contacted with the medicament, wherein the bispecific antigen-binding molecule comprises:

a first antigen-binding domain (D1); and

a second antigen-binding domain (D2);

wherein D1 specifically binds a first epitope of human MET;

wherein D2 specifically binds a second epitope of human MET;

wherein D1 comprises: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 60; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 62; an HCDR3 comprising the amino acid sequence of SEQ ID NO: 64; an LCDR1 comprising the amino acid sequence of SEQ ID NO: 140; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 142; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 144;

wherein D2 comprises: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 84; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 86; an HCDR3 comprising the amino acid sequence of SEQ ID NO: 88; an LCDR1 comprising the amino acid sequence of SEQ ID NO: 140; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 142; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 144;

wherein the cytotoxin is a maytansinoid; and


wherein the cell to be contacted with the ADC results in killing of the uveal

melanoma cell.

13. The use of claim 12, wherein D1 comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 58 and an LCVR comprising the amino acid sequence of SEQ ID NO: 138.


14. The use of claim 12, wherein D2 comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 82 and an LCVR comprising the amino acid sequence of SEQ ID NO: 138.

15. The use of claim 12, wherein the cytotoxin is conjugated to the bispecific antigen-binding molecule through a linker, and wherein the cytotoxin is:




wherein the is the bond to a linker.

16. The use of claim 15, wherein the linker is:




wherein the bond noted with represents the bond to the bispecific antigen-binding molecule and the bond noted with represents the bond to the cytotoxin.

17. The use of claim 12, wherein the cytotoxin is conjugated to the bispecific antigen-binding molecule through a linker, and wherein the cytotoxin is:



wherein the  is the bond to the linker.

18. The use of claim 17, wherein the linker is:



wherein the bond noted with  represents the bond to the bispecific antigen-binding molecule and the bond noted with  represents the bond to the cytotoxin.

19. Use of an antibody-drug conjugate (ADC) comprising a bispecific antigen-binding molecule and a cytotoxin in the manufacture of a medicament for treating c-Met expressing uveal melanoma, wherein a c-Met expressing uveal melanoma cell is to be contacted *in vivo* with the medicament, wherein the cell to be contacted with the medicament induces mitotic arrest of the cell, wherein the bispecific antigen-binding molecule comprises:

a first antigen-binding domain (D1); and

a second antigen-binding domain (D2);

wherein D1 specifically binds a first epitope of human MET;

wherein D2 specifically binds a second epitope of human MET;

wherein D1 comprises: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 60; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 62; an HCDR3 comprising the amino acid sequence of SEQ ID NO: 64; an LCDR1 comprising the amino acid sequence of SEQ ID NO: 140; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 142; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 144;

wherein D2 comprises: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 84; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 86; an HCDR3 comprising the amino acid sequence of SEQ ID NO: 88; an LCDR1 comprising the amino acid sequence of SEQ ID NO: 140; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 142; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 144;


wherein the cytotoxin is a maytansinoid; and

wherein the cell *in vivo* to be contacted with the ADC results in killing of the uveal melanoma cell.

20. The use of claim 19, wherein D1 comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 58 and an LCVR comprising the amino acid sequence of SEQ ID NO: 138.


21. The use of claim 19, wherein D2 comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 82 and an LCVR comprising the amino acid sequence of SEQ ID NO: 138.

22. The use of claim 19, wherein the cytotoxin is conjugated to the bispecific antigen-binding molecule through a linker, and wherein the cytotoxin is:




wherein the  is the bond to a linker.

23. The use of claim 22, wherein the linker is:




wherein the bond noted with  represents the bond to the bispecific antigen-binding molecule and the bond noted with  represents the bond to the cytotoxin.

24. The use of claim 19, wherein the cytotoxin is conjugated to the bispecific antigen-binding molecule through a linker, and wherein the cytotoxin is:



wherein the  is the bond to the linker.

25. The use of claim 24, wherein the linker is:



wherein the bond noted with  represents the bond to the bispecific antigen-binding molecule and the bond noted with  represents the bond to the cytotoxin.